Akeso Reports Full-Year 2025 Financial Results

Core Insights - Akeso reported a record commercial sales revenue of RMB3,033.1 million for 2025, marking a 51.48% year-on-year increase, driven by strong clinical validation and adoption of its products [1][2][14] - The company is advancing its innovative oncology portfolio with the introduction of bispecific and trispecific antibodies, aiming to address unmet medical needs in various cancer types [7][8][10] Commercial Operations - Akeso's products are now fully included in China's National Reimbursement Drug List (NRDL), enhancing market access and positioning for growth in 2026 [1][2] - The company achieved significant sales growth due to the successful adoption of its approved products by healthcare professionals and patients [1][14] Advanced Clinical Development - Ivonescimab, the world's first PD-1/VEGF bispecific antibody, has treated approximately 70,000 patients and has secured two approved lung cancer indications in China [2][4] - Cadonilimab, the first PD-1/CTLA-4 bispecific antibody, has shown clinical benefits across multiple tumor types, with around 120,000 patients treated [5][6] Oncology Therapy Matrix - Akeso is expanding its oncology portfolio through the development of next-generation antibody-drug conjugates (ADCs) and trispecific antibodies, aiming to overcome limitations of traditional ADCs [7][8] - The company is conducting 12 registrational or Phase III clinical trials for cadonilimab, targeting major cancer types and addressing significant unmet medical needs [6][7] AI-Powered R&D - Akeso is integrating AI across its R&D and manufacturing processes, enhancing its drug discovery capabilities and accelerating the development of innovative therapies [11][12] - The company has established a comprehensive AI technology matrix that supports high-precision engineering from sequence design to clinical development [12] Strategic Vision - The company aims to deliver transformative medicines globally, with over ten products in international trials, including ivonescimab and cadonilimab [16] - Akeso is focused on expanding its therapeutic reach beyond oncology into immune-related diseases, leveraging its bispecific and multispecific antibody platforms [10][15]